These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 25144147)

  • 21. [Treatment of overactive urinary bladder with imperative urinary incontinence in women].
    Neĭmark AI; Riapolova MV; Mel'nik MA
    Urologiia; 2010; (2):36-8. PubMed ID: 20967993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.
    Oelke M; Bachmann A; Descazeaud A; Emberton M; Gravas S; Michel MC; N'dow J; Nordling J; de la Rosette JJ;
    Eur Urol; 2013 Jul; 64(1):118-40. PubMed ID: 23541338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.
    Khullar V; Amarenco G; Angulo JC; Cambronero J; Høye K; Milsom I; Radziszewski P; Rechberger T; Boerrigter P; Drogendijk T; Wooning M; Chapple C
    Eur Urol; 2013 Feb; 63(2):283-95. PubMed ID: 23182126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medical management of lower urinary tract symptoms in men with benign prostatic enlargement.
    Marberger M
    Adv Ther; 2013 Apr; 30(4):309-19. PubMed ID: 23584673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study).
    Yamanishi T; Kaga K; Sakata K; Yokoyama T; Kageyama S; Fuse M; Tokunaga S
    Neurourol Urodyn; 2020 Feb; 39(2):804-812. PubMed ID: 31961963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
    Chapple CR; Cardozo L; Nitti VW; Siddiqui E; Michel MC
    Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update.
    Athanasopoulos A; Chapple C; Fowler C; Gratzke C; Kaplan S; Stief C; Tubaro A
    Eur Urol; 2011 Jul; 60(1):94-105. PubMed ID: 21497434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mirabegron for male lower urinary tract symptoms.
    Suarez O; Osborn D; Kaufman M; Reynolds WS; Dmochowski R
    Curr Urol Rep; 2013 Dec; 14(6):580-4. PubMed ID: 23913200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [MIRABEGRON--A NEW DRUG FOR TREATMENT OF OVERACTIVE BLADDER].
    Kasjan GR
    Urologiia; 2015; (4):121-4. PubMed ID: 26665779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine.
    Sebastianelli A; Russo GI; Kaplan SA; McVary KT; Moncada I; Gravas S; Chapple C; Morgia G; Serni S; Gacci M
    Int J Urol; 2018 Mar; 25(3):196-205. PubMed ID: 29205506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rate and associated factors of solifenacin add-on after tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms.
    Lee HN; Lee KS; Kim JC; Chung BH; Kim CS; Lee JG; Kim DK; Park CH; Park JK; Hong SJ
    Int J Clin Pract; 2015 Apr; 69(4):444-53. PubMed ID: 25363606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
    Cardozo L; Hessdörfer E; Milani R; Arañó P; Dewilde L; Slack M; Drogendijk T; Wright M; Bolodeoku J;
    BJU Int; 2008 Nov; 102(9):1120-7. PubMed ID: 18990175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Solifenacin in women with de novo overactive bladder after tension-free obturator vaginal tape--is it effective?
    Serati M; Braga A; Sorice P; Siesto G; Salvatore S; Ghezzi F
    J Urol; 2014 May; 191(5):1322-6. PubMed ID: 24148761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New strategies in treating male lower urinary tract symptoms.
    Füllhase C; Soler R; Gratzke C
    Curr Opin Urol; 2014 Jan; 24(1):29-35. PubMed ID: 24285261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Solifenacin.
    Kreder KJ
    Urol Clin North Am; 2006 Nov; 33(4):483-90, ix. PubMed ID: 17011384
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Solifenacin or mirabegron could improve persistent overactive bladder symptoms after dutasteride treatment in patients with benign prostatic hyperplasia.
    Maeda T; Kikuchi E; Hasegawa M; Ishioka K; Hagiwara M; Miyazaki Y; Shinojima T; Miyajima A; Oya M
    Urology; 2015 May; 85(5):1151-1155. PubMed ID: 25770728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment with solifenacin reduces urinary urgency and improves quality of life. Results of the non-interventional CAP-study].
    Kalchthaler M; Mühlich S; Rothe P
    MMW Fortschr Med; 2011 Jan; 152 Suppl 4():119-24. PubMed ID: 21598462
    [No Abstract]   [Full Text] [Related]  

  • 38. Co-administration of an α(1) -blocker improves the efficacy and safety of antimuscarinic agents in rats with detrusor overactivity.
    Nagase K; Ito H; Aoki Y; Tanase K; Akino H; Yokoyama O
    Int J Urol; 2011 Dec; 18(12):836-43. PubMed ID: 21995543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Solifenacin succinate for the treatment of symptoms of overactive bladder.
    Maniscalco M; Singh-Franco D; Wolowich WR; Torres-Colón R
    Clin Ther; 2006 Sep; 28(9):1247-72. PubMed ID: 17062299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A drug safety evaluation of mirabegron in the management of overactive bladder.
    Robinson D; Thiagamoorthy G; Cardozo L
    Expert Opin Drug Saf; 2016 May; 15(5):689-96. PubMed ID: 26980445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.